Viragen Licenses 'Anti-CD55 Antibody' Cancer Therapy from Cancer Research Technology
Viragen, Inc. and Cancer Research Technology Limited (U.K.) announced a license agreement that provides Viragen with worldwide exclusive rights to commercialize the anti-CD55 antibody, which is currently in preclinical development for the treatment of a broad range of cancers. Financial terms were not disclosed.
"Based on the results of our promising preliminary in vitro evaluations utilizing this novel anti-cancer agent, we are pleased to report that we have exercised our option to acquire exclusive global development and marketing rights to the anti-CD55 antibody," stated Viragen's President and CEO, Mr. Charles A. Rice. "As a monotherapy, or in combination with other anti-cancer therapies, we believe this antibody represents a potentially efficacious treatment for a broad range of tumors, including breast, ovarian and colorectal cancers."
Viragen recently reported that the anti-CD55 antibody, known as VG102, was able to enhance the action of Rituxan® (Rituximab), resulting in the significant increase in the destruction of cancer cells in vitro, indicating the potential of the agent to be used effectively in combination with other therapies.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.